Cargando…

800. Drug-Resistant TB: An Experience From Qatar

BACKGROUND: Drug-resistant tuberculosis (DR-TB) is an important issue for public health. This study was conducted to evaluate the characteristics, treatment outcome, and risk factors associated with 223 DR-TB cases in the State of Qatar. METHODS: A descriptive records-based retrospective study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Maisa, Alhowady, Faraj, Munir, Waqar, Almaslamani, Muna, Alkhal, Abdulatif, Alswaidi, Zubiada, Ziglam, Hisham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253567/
http://dx.doi.org/10.1093/ofid/ofy210.807
_version_ 1783373525489287168
author Ali, Maisa
Alhowady, Faraj
Munir, Waqar
Almaslamani, Muna
Alkhal, Abdulatif
Alswaidi, Zubiada
Ziglam, Hisham
author_facet Ali, Maisa
Alhowady, Faraj
Munir, Waqar
Almaslamani, Muna
Alkhal, Abdulatif
Alswaidi, Zubiada
Ziglam, Hisham
author_sort Ali, Maisa
collection PubMed
description BACKGROUND: Drug-resistant tuberculosis (DR-TB) is an important issue for public health. This study was conducted to evaluate the characteristics, treatment outcome, and risk factors associated with 223 DR-TB cases in the State of Qatar. METHODS: A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010–March 2015. Demographic and clinical data extracted included: patient’s age, sex, and country of origin; disease site (pulmonary or extra-pulmonary); presence of comorbidities, HIV/AIDS status, previous chemoprophylaxis and/or previous treatment for TB, and anti-TB drug resistance the resistance pattern of isolated mycobacteria. The sputum culture conversion rate and treatment outcome was assessed for the patient who completed their treatment in Qatar RESULTS: Of 3,301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to one or more first-line drugs, to isoniazid in 3.1% (n = 102), streptomycin in 1.2% (n = 41), rifampicin in 0.2% (n = 6), ethambutol in 0.15% (n = 5), and multi-drug resistance in 1.2% (n = 38) of patients. Among the resistant TB patients, more common demographic characteristics were former resident of Indian subcontinent (64.1%). A history of anti-TB treatment was not a risk factor with drug resistance in our cohort. Only 111 (49.7%) patients were tested for HIV antibodies and the results were all negative. There was significant correlation between the type of drug-resistance and CXR finding (23.3% had cavity—P = 0.019). Sputum culture conversion to negative at 2 month of therapy was 94% (n = 101), whereas 122 cases lost follow-up. The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment, show cure rate of 97.6%, and relapse of 2.4%. However, 137 cases (61.4% from total) they left the country before completion of therapy. CONCLUSION: Drug-resistant TB in Qatar is influenced by migration, especially from the Indian subcontinent, where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug susceptibility testing should be the standard of care to avoid further transmission and improve TB control. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253567
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62535672018-11-28 800. Drug-Resistant TB: An Experience From Qatar Ali, Maisa Alhowady, Faraj Munir, Waqar Almaslamani, Muna Alkhal, Abdulatif Alswaidi, Zubiada Ziglam, Hisham Open Forum Infect Dis Abstracts BACKGROUND: Drug-resistant tuberculosis (DR-TB) is an important issue for public health. This study was conducted to evaluate the characteristics, treatment outcome, and risk factors associated with 223 DR-TB cases in the State of Qatar. METHODS: A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010–March 2015. Demographic and clinical data extracted included: patient’s age, sex, and country of origin; disease site (pulmonary or extra-pulmonary); presence of comorbidities, HIV/AIDS status, previous chemoprophylaxis and/or previous treatment for TB, and anti-TB drug resistance the resistance pattern of isolated mycobacteria. The sputum culture conversion rate and treatment outcome was assessed for the patient who completed their treatment in Qatar RESULTS: Of 3,301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to one or more first-line drugs, to isoniazid in 3.1% (n = 102), streptomycin in 1.2% (n = 41), rifampicin in 0.2% (n = 6), ethambutol in 0.15% (n = 5), and multi-drug resistance in 1.2% (n = 38) of patients. Among the resistant TB patients, more common demographic characteristics were former resident of Indian subcontinent (64.1%). A history of anti-TB treatment was not a risk factor with drug resistance in our cohort. Only 111 (49.7%) patients were tested for HIV antibodies and the results were all negative. There was significant correlation between the type of drug-resistance and CXR finding (23.3% had cavity—P = 0.019). Sputum culture conversion to negative at 2 month of therapy was 94% (n = 101), whereas 122 cases lost follow-up. The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment, show cure rate of 97.6%, and relapse of 2.4%. However, 137 cases (61.4% from total) they left the country before completion of therapy. CONCLUSION: Drug-resistant TB in Qatar is influenced by migration, especially from the Indian subcontinent, where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug susceptibility testing should be the standard of care to avoid further transmission and improve TB control. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253567/ http://dx.doi.org/10.1093/ofid/ofy210.807 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ali, Maisa
Alhowady, Faraj
Munir, Waqar
Almaslamani, Muna
Alkhal, Abdulatif
Alswaidi, Zubiada
Ziglam, Hisham
800. Drug-Resistant TB: An Experience From Qatar
title 800. Drug-Resistant TB: An Experience From Qatar
title_full 800. Drug-Resistant TB: An Experience From Qatar
title_fullStr 800. Drug-Resistant TB: An Experience From Qatar
title_full_unstemmed 800. Drug-Resistant TB: An Experience From Qatar
title_short 800. Drug-Resistant TB: An Experience From Qatar
title_sort 800. drug-resistant tb: an experience from qatar
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253567/
http://dx.doi.org/10.1093/ofid/ofy210.807
work_keys_str_mv AT alimaisa 800drugresistanttbanexperiencefromqatar
AT alhowadyfaraj 800drugresistanttbanexperiencefromqatar
AT munirwaqar 800drugresistanttbanexperiencefromqatar
AT almaslamanimuna 800drugresistanttbanexperiencefromqatar
AT alkhalabdulatif 800drugresistanttbanexperiencefromqatar
AT alswaidizubiada 800drugresistanttbanexperiencefromqatar
AT ziglamhisham 800drugresistanttbanexperiencefromqatar